Æterna Zentarisの収益Y / Y
Æterna Zentarisの収益Y / Yは何ですか。
Æterna Zentaris, Inc.の収益Y / Yは-61.94%です。
収益Y / Yの定義は何ですか。
過去3年間の年間収益の伸びは、過去3年間で平均した1年間の収益成長率です。
The yearly revenue growth rate is calculated as the percentage change in revenue over the trailing twelve months. For this specific metric, the calculation takes into account a series of the last eight quarterly revenues. The revenue growth is useful for determining the success of the company expanding its main business. Revenue growth of 5% to 10% is usually considered good for large-cap companies. For other companies, a sales growth of over 10% is more desirable.
TSXのセクタHealth Careにおける収益Y / Yの企業と比べるÆterna Zentaris
Æterna Zentarisは何をしますか。
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and to develop human 3D intestinal tissue models to study infection biology; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd., Novo Nordisk Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.
Æterna Zentarisと類似の収益y / y
- Atheneの収益Y / Yは-62.32%です。
- Zevra Therapeutics Incの収益Y / Yは-62.30%です。
- Supreme Infrastructure Indiaの収益Y / Yは-62.29%です。
- The Parkmead Plcの収益Y / Yは-62.08%です。
- Sintex Plastics Technologyの収益Y / Yは-62.08%です。
- Garnet Internationalの収益Y / Yは-62.00%です。
- Æterna Zentarisの収益Y / Yは-61.94%です。
- mCloud Technologiesの収益Y / Yは-61.80%です。
- PDL Biopharma Incの収益Y / Yは-61.69%です。
- Chesapeake Corp 5% Cum Cの収益Y / Yは-61.69%です。
- Manulife Corp Non Cumの収益Y / Yは-61.64%です。
- New York Mortgage Trust Incの収益Y / Yは-61.63%です。
- Ruixin Internationalの収益Y / Yは-61.59%です。